AGPCNP-AANP: Advanced Gerontology Primary Care
NP Prep with Detailed Rationales
Course Code: AGPCNP-AANP
Course Name: AANP Adult-Gerontology Primary Care NP Exam Study
Topic: Advanced Clinical Management, Pharmacology, and Differential
Diagnosis
Academic Year: 2026/2027
1. A 72-year-old male with a history of heart failure with reduced ejection
fraction (HFrEF, EF 35%) and stage 3a chronic kidney disease presents
for a routine wellness exam. He is currently taking lisinopril 20 mg daily,
carvedilol 25 mg twice daily, and furosemide 40 mg daily. His vital signs
reveal a blood pressure of 128/78 mmHg and a heart rate of 68 bpm.
Laboratory values show a stable serum potassium of 4.8 mEq/L and an
eGFR of 52 mL/min/1.73m². According to current guideline-directed
medical therapy (GDMT) for HFrEF, which of the following represents the
most appropriate next step in his pharmacological management?
, A. Increase the furosemide dosage to 80 mg daily to ensure long-term
hypervolemia prevention.
B. Switch lisinopril to sacubitril/valsartan (ARNI) after a 36-hour
washout period.
C. Discontinue carvedilol immediately and initiate ivabradine monotherapy.
D. Add a non-dihydropyridine calcium channel blocker such as diltiazem for
strict blood pressure control.
CORRECT ANSWER: B
RATIONALE: In patients with HFrEF who tolerate an ACE inhibitor or
ARB well, clinical guidelines recommend upgrading to an angiotensin
receptor-neprilysin inhibitor (ARNI) like sacubitril/valsartan to further
reduce cardiovascular morbidity and all-cause mortality. A mandatory 36-
hour washout period is required when switching from an ACE inhibitor to
prevent an increased risk of angioedema. Option A is incorrect because
increasing loop diuretics is only indicated for active fluid overload, not as a
baseline mortality intervention. Option C is incorrect as beta-blockers are
foundational life-prolonging therapies. Option D is incorrect because non-
dihydropyridine calcium channel blockers exert negative inotropic effects
and are contraindicated in HFrEF.
2. An 80-year-old female presents to the primary care clinic with newly
diagnosed paroxysmal atrial fibrillation. Her comorbidities include
hypertension controlled on amlodipine and type 2 diabetes mellitus. Her
current resting heart rate is 84 bpm, blood pressure is 132/82 mmHg, and she
has no active bleeding vulnerabilities or history of hemorrhagic events. Her
calculated CHA₂DS₂-VASc score is 4. What is the most appropriate
antithrombotic strategy for this patient?
A. Initiate aspirin 81 mg daily combined with clopidogrel 75 mg daily.
B. Recommend aspirin 81 mg daily as safe monotherapy based on her
advanced age.
C. Initiate a direct oral anticoagulant (DOAC) such as apixaban.
D. Defer pharmacotherapy, prescribe lifestyle modifications, and re-evaluate
her score in six months.
CORRECT ANSWER: C
RATIONALE: A CHA₂DS₂-VASc score of 4 in a female patient
represents a high annual risk for a thromboembolic stroke, making oral
, anticoagulation strongly indicated. Direct oral anticoagulants (DOACs)
like apixaban or rivaroxaban are preferred first-line choices over warfarin
due to a superior safety profile and lower risk of intracranial hemorrhage.
Options A and B are incorrect because aspirin monotherapy or dual
antiplatelet therapy (DAPT) is significantly less effective for stroke
prevention in non-valvular atrial fibrillation and carries a comparable
bleeding risk in older adults. Option D is incorrect because delaying
anticoagulation unnecessarily exposes a high-risk patient to a devastating
stroke.
3. A 65-year-old male with a 45 pack-year smoking history presents with a
chronic productive cough and progressive dyspnea on exertion. Spirometry
confirms a post-bronchodilator FEV1/FVC ratio of 0.62 and an FEV1 of
48% predicted. He reports experiencing two moderate COPD exacerbations
treated with oral corticosteroids and antibiotics in the past 12 months, but
required no hospitalizations. His current COPD Assessment Test (CAT)
score is 18. According to the updated GOLD Guidelines, how should this
patient be categorized and what is the preferred initial maintenance
pharmacotherapy?
A. Group A; initiate a short-acting beta-agonist (SABA) as needed.
B. Group B; initiate a single long-acting beta-agonist (LABA).
C. Group E; initiate a combination long-acting muscarinic antagonist
and long-acting beta-agonist (LAMA/LABA).
D. Group D; initiate an inhaled corticosteroid (ICS) plus LABA
combination.
CORRECT ANSWER: C
RATIONALE: The updated GOLD guidelines consolidated high-risk
categories (formerly Groups C and D) into a single classification: Group E.
This group encompasses any patient who has experienced 2 or more
moderate exacerbations or at least 1 exacerbation leading to a hospital
admission within the past year, regardless of their baseline symptom score.
The preferred initial maintenance therapy for Group E is a dual long-acting
bronchodilator combination (LAMA/LABA). Option A is for low-risk, low-
symptom patients. Option B is for low-risk, high-symptom patients. Option
D is incorrect because ICS therapy is not first-line unless blood eosinophils
are markedly elevated (>300 cells/mcL) or a history of asthma coexists.
, 4. A 58-year-old female with type 2 diabetes mellitus, established
atherosclerotic cardiovascular disease (ASCVD), and a stable eGFR of 42
mL/min/1.73m² presents with an elevated HbA1c of 8.2% despite an
optimized daily regimen of metformin. She is highly motivated to avoid
hypoglycemia and wants an agent that protects her remaining renal function.
According to the American Diabetes Association (ADA) Standards of Care,
which class of medication should be prioritized next?
A. Sodium-glucose cotransporter-2 inhibitor (SGLT2i).
B. Second-generation sulfonylurea such as glipizide.
C. Basal insulin glargine adjusted to strict fasting targets.
D. Dipeptidyl peptidase-4 inhibitor (DPP-4i) such as sitagliptin.
CORRECT ANSWER: A
RATIONALE: For patients with type 2 diabetes and concurrent chronic
kidney disease (CKD) or established ASCVD, an SGLT2 inhibitor (e.g.,
empagliflozin, dapagliflozin) is strongly indicated as an add-on therapy.
SGLT2 inhibitors offer independent cardiorenal protection, significantly
slowing the progression of diabetic nephropathy and reducing heart failure
hospitalizations, while maintaining a very low risk for hypoglycemia. Option
B is incorrect because sulfonylureas carry high hypoglycemia risks and
accumulate in renal impairment. Option C is effective for glycemic control
but does not provide specific cardiorenal risk reduction. Option D lacks the
robust cardiovascular and renal organ-protective benefits demonstrated by
SGLT2 inhibitors.
5. An 84-year-old male is brought to the clinic by his daughter, who reports
that he has become increasingly confused, somnolent, and uncoordinated
over the past week following a minor household stumble. The family notes
he was given a neighbor's over-the-counter sleep aid. Which medication
class is most notorious for precipitating acute delirium and falls in geriatric
patients according to the Beers Criteria?
A. Selective serotonin reuptake inhibitors (SSRIs).
B. HMG-CoA reductase inhibitors (Statins).
C. First-generation antihistamines and benzodiazepines.
D. Short-acting beta-2 agonists (SABAs).
CORRECT ANSWER: C
RATIONALE: According to the American Geriatrics Society Beers
NP Prep with Detailed Rationales
Course Code: AGPCNP-AANP
Course Name: AANP Adult-Gerontology Primary Care NP Exam Study
Topic: Advanced Clinical Management, Pharmacology, and Differential
Diagnosis
Academic Year: 2026/2027
1. A 72-year-old male with a history of heart failure with reduced ejection
fraction (HFrEF, EF 35%) and stage 3a chronic kidney disease presents
for a routine wellness exam. He is currently taking lisinopril 20 mg daily,
carvedilol 25 mg twice daily, and furosemide 40 mg daily. His vital signs
reveal a blood pressure of 128/78 mmHg and a heart rate of 68 bpm.
Laboratory values show a stable serum potassium of 4.8 mEq/L and an
eGFR of 52 mL/min/1.73m². According to current guideline-directed
medical therapy (GDMT) for HFrEF, which of the following represents the
most appropriate next step in his pharmacological management?
, A. Increase the furosemide dosage to 80 mg daily to ensure long-term
hypervolemia prevention.
B. Switch lisinopril to sacubitril/valsartan (ARNI) after a 36-hour
washout period.
C. Discontinue carvedilol immediately and initiate ivabradine monotherapy.
D. Add a non-dihydropyridine calcium channel blocker such as diltiazem for
strict blood pressure control.
CORRECT ANSWER: B
RATIONALE: In patients with HFrEF who tolerate an ACE inhibitor or
ARB well, clinical guidelines recommend upgrading to an angiotensin
receptor-neprilysin inhibitor (ARNI) like sacubitril/valsartan to further
reduce cardiovascular morbidity and all-cause mortality. A mandatory 36-
hour washout period is required when switching from an ACE inhibitor to
prevent an increased risk of angioedema. Option A is incorrect because
increasing loop diuretics is only indicated for active fluid overload, not as a
baseline mortality intervention. Option C is incorrect as beta-blockers are
foundational life-prolonging therapies. Option D is incorrect because non-
dihydropyridine calcium channel blockers exert negative inotropic effects
and are contraindicated in HFrEF.
2. An 80-year-old female presents to the primary care clinic with newly
diagnosed paroxysmal atrial fibrillation. Her comorbidities include
hypertension controlled on amlodipine and type 2 diabetes mellitus. Her
current resting heart rate is 84 bpm, blood pressure is 132/82 mmHg, and she
has no active bleeding vulnerabilities or history of hemorrhagic events. Her
calculated CHA₂DS₂-VASc score is 4. What is the most appropriate
antithrombotic strategy for this patient?
A. Initiate aspirin 81 mg daily combined with clopidogrel 75 mg daily.
B. Recommend aspirin 81 mg daily as safe monotherapy based on her
advanced age.
C. Initiate a direct oral anticoagulant (DOAC) such as apixaban.
D. Defer pharmacotherapy, prescribe lifestyle modifications, and re-evaluate
her score in six months.
CORRECT ANSWER: C
RATIONALE: A CHA₂DS₂-VASc score of 4 in a female patient
represents a high annual risk for a thromboembolic stroke, making oral
, anticoagulation strongly indicated. Direct oral anticoagulants (DOACs)
like apixaban or rivaroxaban are preferred first-line choices over warfarin
due to a superior safety profile and lower risk of intracranial hemorrhage.
Options A and B are incorrect because aspirin monotherapy or dual
antiplatelet therapy (DAPT) is significantly less effective for stroke
prevention in non-valvular atrial fibrillation and carries a comparable
bleeding risk in older adults. Option D is incorrect because delaying
anticoagulation unnecessarily exposes a high-risk patient to a devastating
stroke.
3. A 65-year-old male with a 45 pack-year smoking history presents with a
chronic productive cough and progressive dyspnea on exertion. Spirometry
confirms a post-bronchodilator FEV1/FVC ratio of 0.62 and an FEV1 of
48% predicted. He reports experiencing two moderate COPD exacerbations
treated with oral corticosteroids and antibiotics in the past 12 months, but
required no hospitalizations. His current COPD Assessment Test (CAT)
score is 18. According to the updated GOLD Guidelines, how should this
patient be categorized and what is the preferred initial maintenance
pharmacotherapy?
A. Group A; initiate a short-acting beta-agonist (SABA) as needed.
B. Group B; initiate a single long-acting beta-agonist (LABA).
C. Group E; initiate a combination long-acting muscarinic antagonist
and long-acting beta-agonist (LAMA/LABA).
D. Group D; initiate an inhaled corticosteroid (ICS) plus LABA
combination.
CORRECT ANSWER: C
RATIONALE: The updated GOLD guidelines consolidated high-risk
categories (formerly Groups C and D) into a single classification: Group E.
This group encompasses any patient who has experienced 2 or more
moderate exacerbations or at least 1 exacerbation leading to a hospital
admission within the past year, regardless of their baseline symptom score.
The preferred initial maintenance therapy for Group E is a dual long-acting
bronchodilator combination (LAMA/LABA). Option A is for low-risk, low-
symptom patients. Option B is for low-risk, high-symptom patients. Option
D is incorrect because ICS therapy is not first-line unless blood eosinophils
are markedly elevated (>300 cells/mcL) or a history of asthma coexists.
, 4. A 58-year-old female with type 2 diabetes mellitus, established
atherosclerotic cardiovascular disease (ASCVD), and a stable eGFR of 42
mL/min/1.73m² presents with an elevated HbA1c of 8.2% despite an
optimized daily regimen of metformin. She is highly motivated to avoid
hypoglycemia and wants an agent that protects her remaining renal function.
According to the American Diabetes Association (ADA) Standards of Care,
which class of medication should be prioritized next?
A. Sodium-glucose cotransporter-2 inhibitor (SGLT2i).
B. Second-generation sulfonylurea such as glipizide.
C. Basal insulin glargine adjusted to strict fasting targets.
D. Dipeptidyl peptidase-4 inhibitor (DPP-4i) such as sitagliptin.
CORRECT ANSWER: A
RATIONALE: For patients with type 2 diabetes and concurrent chronic
kidney disease (CKD) or established ASCVD, an SGLT2 inhibitor (e.g.,
empagliflozin, dapagliflozin) is strongly indicated as an add-on therapy.
SGLT2 inhibitors offer independent cardiorenal protection, significantly
slowing the progression of diabetic nephropathy and reducing heart failure
hospitalizations, while maintaining a very low risk for hypoglycemia. Option
B is incorrect because sulfonylureas carry high hypoglycemia risks and
accumulate in renal impairment. Option C is effective for glycemic control
but does not provide specific cardiorenal risk reduction. Option D lacks the
robust cardiovascular and renal organ-protective benefits demonstrated by
SGLT2 inhibitors.
5. An 84-year-old male is brought to the clinic by his daughter, who reports
that he has become increasingly confused, somnolent, and uncoordinated
over the past week following a minor household stumble. The family notes
he was given a neighbor's over-the-counter sleep aid. Which medication
class is most notorious for precipitating acute delirium and falls in geriatric
patients according to the Beers Criteria?
A. Selective serotonin reuptake inhibitors (SSRIs).
B. HMG-CoA reductase inhibitors (Statins).
C. First-generation antihistamines and benzodiazepines.
D. Short-acting beta-2 agonists (SABAs).
CORRECT ANSWER: C
RATIONALE: According to the American Geriatrics Society Beers
